On May 20, 2024 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, reported the completion of its purchase of antibodies and related assets from Atreca, Inc (Press release, Immunome, MAY 20, 2024, View Source [SID1234643474]). Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical development milestones. Immunome received the rights to 28 antibodies as well as certain materials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Novel and underexplored targets are central to Immunome’s pipeline strategy," said Jack Higgins, PhD, Chief Scientific Officer. "The antibodies acquired from Atreca add to our ADC toolbox, complementing our existing discovery programs pursuing undisclosed targets."

Added Clay Siegall, PhD, President and Chief Executive Officer, "Immunome intends to further expand its ADC portfolio through cost-effective business development, rigorous discovery efforts, and disciplined development. We believe this purchase accelerates our efforts to bring innovative therapies to cancer patients."